Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease

R. C. Dodel, Yansheng Du, C. Depboylu, H. Hampel, L. Frölich, A. Haag, U. Hemmeter, S. Paulsen, S. J. Teipel, S. Brettschneider, A. Spottke, C. Nölker, H. J. Möller, X. Wei, Martin Farlow, N. Sommer, W. H. Oertel

Research output: Contribution to journalArticle

291 Citations (Scopus)

Abstract

Objective: Active or passive immunisation can mitigate plaque pathology in murine models of Alzheimer's disease (AD). Recently, it has been shown that antibodies against β-amyloid (Aβ) are present in human immunoglobulin preparations (IVIgG), which specifically recognise and inhibit the neurotoxic effects of Aβ. This study reports the results from a pilot study using IVIgG in patients with AD. Methods: Five patients with AD were enrolled and received monthly IVIgG over a 6 month period. Efficacy assessment included total Aβ/Aβ1-42 measured in the CSF/serum as well as effects on cognition (ADAS-cog; CERAD) at baseline and at 6 months following IVIgG. Results: Following IVIgG, total Aβ levels in the CSF decreased by 30.1% (17.3-43.5%) compared to baseline (p<0.05). Total Aβ increased in the serum by 233% (p<0.05). No significant change was found in Aβ1-42 levels in the CSF/serum. Using ADAS-cog, an improvement of 3.7±2.9 points was detected. Scores in the MMSE were essentially unchanged (improved in four patients, stable in one patient) following IVIgG compared to baseline. Conclusion: Although the sample size of this pilot study is too small to draw a clear conclusion, the results of this pilot study provide evidence for a more detailed investigation of IVIgG for the treatment of AD.

Original languageEnglish
Pages (from-to)1472-1474
Number of pages3
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume75
Issue number10
DOIs
StatePublished - Oct 2004

Fingerprint

Intravenous Immunoglobulins
Amyloid
Alzheimer Disease
Antibodies
Serum
Passive Immunization
Therapeutics
Sample Size
Cognition
Immunoglobulins
Vaccination
Pathology

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Psychiatry and Mental health

Cite this

Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. / Dodel, R. C.; Du, Yansheng; Depboylu, C.; Hampel, H.; Frölich, L.; Haag, A.; Hemmeter, U.; Paulsen, S.; Teipel, S. J.; Brettschneider, S.; Spottke, A.; Nölker, C.; Möller, H. J.; Wei, X.; Farlow, Martin; Sommer, N.; Oertel, W. H.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 75, No. 10, 10.2004, p. 1472-1474.

Research output: Contribution to journalArticle

Dodel, RC, Du, Y, Depboylu, C, Hampel, H, Frölich, L, Haag, A, Hemmeter, U, Paulsen, S, Teipel, SJ, Brettschneider, S, Spottke, A, Nölker, C, Möller, HJ, Wei, X, Farlow, M, Sommer, N & Oertel, WH 2004, 'Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease', Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 10, pp. 1472-1474. https://doi.org/10.1136/jnnp.2003.033399
Dodel, R. C. ; Du, Yansheng ; Depboylu, C. ; Hampel, H. ; Frölich, L. ; Haag, A. ; Hemmeter, U. ; Paulsen, S. ; Teipel, S. J. ; Brettschneider, S. ; Spottke, A. ; Nölker, C. ; Möller, H. J. ; Wei, X. ; Farlow, Martin ; Sommer, N. ; Oertel, W. H. / Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. In: Journal of Neurology, Neurosurgery and Psychiatry. 2004 ; Vol. 75, No. 10. pp. 1472-1474.
@article{8285a4f5f8ea40d5ae92130cb6ef0f2a,
title = "Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease",
abstract = "Objective: Active or passive immunisation can mitigate plaque pathology in murine models of Alzheimer's disease (AD). Recently, it has been shown that antibodies against β-amyloid (Aβ) are present in human immunoglobulin preparations (IVIgG), which specifically recognise and inhibit the neurotoxic effects of Aβ. This study reports the results from a pilot study using IVIgG in patients with AD. Methods: Five patients with AD were enrolled and received monthly IVIgG over a 6 month period. Efficacy assessment included total Aβ/Aβ1-42 measured in the CSF/serum as well as effects on cognition (ADAS-cog; CERAD) at baseline and at 6 months following IVIgG. Results: Following IVIgG, total Aβ levels in the CSF decreased by 30.1{\%} (17.3-43.5{\%}) compared to baseline (p<0.05). Total Aβ increased in the serum by 233{\%} (p<0.05). No significant change was found in Aβ1-42 levels in the CSF/serum. Using ADAS-cog, an improvement of 3.7±2.9 points was detected. Scores in the MMSE were essentially unchanged (improved in four patients, stable in one patient) following IVIgG compared to baseline. Conclusion: Although the sample size of this pilot study is too small to draw a clear conclusion, the results of this pilot study provide evidence for a more detailed investigation of IVIgG for the treatment of AD.",
author = "Dodel, {R. C.} and Yansheng Du and C. Depboylu and H. Hampel and L. Fr{\"o}lich and A. Haag and U. Hemmeter and S. Paulsen and Teipel, {S. J.} and S. Brettschneider and A. Spottke and C. N{\"o}lker and M{\"o}ller, {H. J.} and X. Wei and Martin Farlow and N. Sommer and Oertel, {W. H.}",
year = "2004",
month = "10",
doi = "10.1136/jnnp.2003.033399",
language = "English",
volume = "75",
pages = "1472--1474",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "10",

}

TY - JOUR

T1 - Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease

AU - Dodel, R. C.

AU - Du, Yansheng

AU - Depboylu, C.

AU - Hampel, H.

AU - Frölich, L.

AU - Haag, A.

AU - Hemmeter, U.

AU - Paulsen, S.

AU - Teipel, S. J.

AU - Brettschneider, S.

AU - Spottke, A.

AU - Nölker, C.

AU - Möller, H. J.

AU - Wei, X.

AU - Farlow, Martin

AU - Sommer, N.

AU - Oertel, W. H.

PY - 2004/10

Y1 - 2004/10

N2 - Objective: Active or passive immunisation can mitigate plaque pathology in murine models of Alzheimer's disease (AD). Recently, it has been shown that antibodies against β-amyloid (Aβ) are present in human immunoglobulin preparations (IVIgG), which specifically recognise and inhibit the neurotoxic effects of Aβ. This study reports the results from a pilot study using IVIgG in patients with AD. Methods: Five patients with AD were enrolled and received monthly IVIgG over a 6 month period. Efficacy assessment included total Aβ/Aβ1-42 measured in the CSF/serum as well as effects on cognition (ADAS-cog; CERAD) at baseline and at 6 months following IVIgG. Results: Following IVIgG, total Aβ levels in the CSF decreased by 30.1% (17.3-43.5%) compared to baseline (p<0.05). Total Aβ increased in the serum by 233% (p<0.05). No significant change was found in Aβ1-42 levels in the CSF/serum. Using ADAS-cog, an improvement of 3.7±2.9 points was detected. Scores in the MMSE were essentially unchanged (improved in four patients, stable in one patient) following IVIgG compared to baseline. Conclusion: Although the sample size of this pilot study is too small to draw a clear conclusion, the results of this pilot study provide evidence for a more detailed investigation of IVIgG for the treatment of AD.

AB - Objective: Active or passive immunisation can mitigate plaque pathology in murine models of Alzheimer's disease (AD). Recently, it has been shown that antibodies against β-amyloid (Aβ) are present in human immunoglobulin preparations (IVIgG), which specifically recognise and inhibit the neurotoxic effects of Aβ. This study reports the results from a pilot study using IVIgG in patients with AD. Methods: Five patients with AD were enrolled and received monthly IVIgG over a 6 month period. Efficacy assessment included total Aβ/Aβ1-42 measured in the CSF/serum as well as effects on cognition (ADAS-cog; CERAD) at baseline and at 6 months following IVIgG. Results: Following IVIgG, total Aβ levels in the CSF decreased by 30.1% (17.3-43.5%) compared to baseline (p<0.05). Total Aβ increased in the serum by 233% (p<0.05). No significant change was found in Aβ1-42 levels in the CSF/serum. Using ADAS-cog, an improvement of 3.7±2.9 points was detected. Scores in the MMSE were essentially unchanged (improved in four patients, stable in one patient) following IVIgG compared to baseline. Conclusion: Although the sample size of this pilot study is too small to draw a clear conclusion, the results of this pilot study provide evidence for a more detailed investigation of IVIgG for the treatment of AD.

UR - http://www.scopus.com/inward/record.url?scp=4644275963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644275963&partnerID=8YFLogxK

U2 - 10.1136/jnnp.2003.033399

DO - 10.1136/jnnp.2003.033399

M3 - Article

C2 - 15377700

AN - SCOPUS:4644275963

VL - 75

SP - 1472

EP - 1474

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 10

ER -